Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E G B Vijverberg

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Prevention of Alzheimer'S Disease|September 29, 2021
Commentary: Aducanumab: Appropriate Use RecommendationsP Scheltens, E G B Vijverberg
Alzheimer'S Research & Therapy|May 19, 2021
A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation studyE A J Willemse, P Scheltens, C E Teunissen, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 10, 2017
[Chronic traumatic encephalopathy: an old acquaintance in athletes]E G B Vijverberg, A C M Pijnenburg, P Scheltens, et al.
Tijdschrift Voor Psychiatrie|May 27, 2021
[Frontotemporal dementia diagnoses within the psychiatric practice: pitfalls and practical tools]W A Krudop, F Gossink, E G B Vijverberg, et al.
Neurobiology of Aging|December 13, 2016
Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's diseaseE G B Vijverberg, B M Tijms, J Dopp, et al.
Alzheimer'S Research & Therapy|August 24, 2021
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIADE G B Vijverberg, T M Axelsen, A R Bihlet, et al.
The Journal of Prevention of Alzheimer'S Disease|October 24, 2023
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease PatientsM Oosthoek, A Lili, A Almeida, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Prevention of Alzheimer'S Disease|September 29, 2021
Commentary: Aducanumab: Appropriate Use RecommendationsP Scheltens, E G B Vijverberg
Alzheimer'S Research & Therapy|May 19, 2021
A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation studyE A J Willemse, P Scheltens, C E Teunissen, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 10, 2017
[Chronic traumatic encephalopathy: an old acquaintance in athletes]E G B Vijverberg, A C M Pijnenburg, P Scheltens, et al.
Tijdschrift Voor Psychiatrie|May 27, 2021
[Frontotemporal dementia diagnoses within the psychiatric practice: pitfalls and practical tools]W A Krudop, F Gossink, E G B Vijverberg, et al.
Neurobiology of Aging|December 13, 2016
Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's diseaseE G B Vijverberg, B M Tijms, J Dopp, et al.
Alzheimer'S Research & Therapy|August 24, 2021
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIADE G B Vijverberg, T M Axelsen, A R Bihlet, et al.
The Journal of Prevention of Alzheimer'S Disease|October 24, 2023
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease PatientsM Oosthoek, A Lili, A Almeida, et al.
Pageof 1